Pharmaceuticals, Biotechnology and Life Sciences
– 44% of patients achieved a response and nearly half (48%) maintained disease control at week 12 (efficacy as secondary…
The U.S. Food and Drug Administration granted Breakthrough Therapy Designation to capmatinib (INC280) as a first-line treatment for patients with metastatic MET exon14 skipping-mutated non-small cell lung cancer (NSCLC), said John Tsai, MD, Head of Global Drug Development and Chief Medical Officer, Novartis.
Mereo BioPharma will present the 6-month interim data from the open label arm of the its Phase 2b dose-ranging clinical study of setrusumab (BPS-804) in adults with Type I, III or IV osteogenesis imperfecta (OI) at the upcoming American Society for Bone and Mineral Research (ASBMR) 2019 Annual Meeting to be held from September 20-23 in Orlando, FL.
Velesco Pharma, is expanding its clinical manufacturing capacity with the purchase and fit-out of a new, state-of-the-art facility in Wixom, Michigan, the company said Wednesday in a press release.
Pacific Biosciences’ Single Molecule, Real-Time Sequencing technology has been selected by the European research program SOLVE-RD to help reveal the genetic mechanisms responsible for rare genetic diseases. As part of this work, scientists will sequence more than 500 whole human genomes with the PacBio Sequel II System to pinpoint disease-causing variants.
Denali Therapeutics Inc., a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, has started dosing in a Phase 1b clinical study of LRRK2 inhibitor DNL151 in patients with Parkinson’s disease, and the launch of its Engage Parkinson’s website.
Beam Therapeutics, a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of financial industry veteran, Terry-Ann Burrell, as chief financial officer. Ms. Burrell joins Beam from J.P. Morgan, where she was a managing director in the healthcare investment banking group.
The Janssen Pharmaceutical Companies of Johnson & Johnson got the FDA’s Breakthrough Therapy Designation for its investigational prophylactic vaccine for the prevention of #respiratory syncytial virus (RSV)- mediated lower respiratory tract disease in adults aged 60 years or older. @JNJNews
Allergan got U.S. Food and Drug Administration (FDA) approval for the use of Juvéderm VOLUMA XC, a hyaluronic acid gel dermal filler, with a TSK STERiGLIDE™ cannula for cheek augmentation to correct age-related volume deficit in the mid-face in adults over 21.
Vertex Pharmaceuticals Incorporated will acquire Semma Therapeutics, a privately held biotechnology company pioneering the use of stem cell-derived human islets as a potentially curative treatment for type 1 diabetes, for $950 million in cash.